165 related articles for article (PubMed ID: 22573014)
21. The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan.
Hsu LA; Teng MS; Ko YL; Chang CJ; Wu S; Wang CL; Hu CF
Clin Chem Lab Med; 2009; 47(2):154-8. PubMed ID: 19191720
[TBL] [Abstract][Full Text] [Related]
22. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
[TBL] [Abstract][Full Text] [Related]
24. PPARD +294C overrepresentation in general and long-lived population in China Bama longevity area and unique relationships between PPARD +294T/C polymorphism and serum lipid profiles.
Luo CY; Liu CW; Ge L; Pang GF; Yang M; Hu CY; Lv ZP; Chen NY; Li HY; Wu HY; Wang YY; Yin RX; Pan SL; Peng JH
Lipids Health Dis; 2015 Mar; 14():17. PubMed ID: 25873088
[TBL] [Abstract][Full Text] [Related]
25. Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia.
Guay SP; Brisson D; Lamarche B; Gaudet D; Bouchard L
Epigenetics; 2014 May; 9(5):718-29. PubMed ID: 24504152
[TBL] [Abstract][Full Text] [Related]
26. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
Le May C; Berger JM; Lespine A; Pillot B; Prieur X; Letessier E; Hussain MM; Collet X; Cariou B; Costet P
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1484-93. PubMed ID: 23559630
[TBL] [Abstract][Full Text] [Related]
27. G-protein estrogen receptor as a regulator of low-density lipoprotein cholesterol metabolism: cellular and population genetic studies.
Hussain Y; Ding Q; Connelly PW; Brunt JH; Ban MR; McIntyre AD; Huff MW; Gros R; Hegele RA; Feldman RD
Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):213-21. PubMed ID: 25395619
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.
Lye SH; Chahil JK; Bagali P; Alex L; Vadivelu J; Ahmad WA; Chan SP; Thong MK; Zain SM; Mohamed R
PLoS One; 2013; 8(4):e60729. PubMed ID: 23593297
[TBL] [Abstract][Full Text] [Related]
29. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
30. Association studies of several cholesterol-related genes (ABCA1, CETP and LIPC) with serum lipids and risk of Alzheimer's disease.
Xiao Z; Wang J; Chen W; Wang P; Zeng H; Chen W
Lipids Health Dis; 2012 Nov; 11():163. PubMed ID: 23181436
[TBL] [Abstract][Full Text] [Related]
31. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
32. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
Awan Z; Baass A; Genest J
Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
[TBL] [Abstract][Full Text] [Related]
33. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
[TBL] [Abstract][Full Text] [Related]
34. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.
Mabuchi H; Nohara A; Noguchi T; Kobayashi J; Kawashiri MA; Inoue T; Mori M; Tada H; Nakanishi C; Yagi K; Yamagishi M; Ueda K; Takegoshi T; Miyamoto S; Inazu A; Koizumi J;
Atherosclerosis; 2014 Sep; 236(1):54-61. PubMed ID: 25014035
[TBL] [Abstract][Full Text] [Related]
35. Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives.
Yang SH; Du Y; Li S; Zhang Y; Xu RX; Zhu CG; Guo YL; Wu NQ; Dong Q; Sun J; Li JJ
Hypertens Res; 2016 Aug; 39(8):598-605. PubMed ID: 27075829
[TBL] [Abstract][Full Text] [Related]
36. Association of MYLIP rs3757354 SNP and several environmental factors with serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
Yan TT; Yin RX; Li Q; Huang P; Zeng XN; Huang KK; Wu DF; Aung LH
Lipids Health Dis; 2012 Oct; 11():141. PubMed ID: 23107276
[TBL] [Abstract][Full Text] [Related]
37. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
[TBL] [Abstract][Full Text] [Related]
38. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
39. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
40. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
